Continuous Renal Replacement Therapy for Children <= 10 kg: A Report from the Prospective Pediatric Continuous Renal Replacement Therapy Registry

University of Alabama at Birmingham, Children's of Alabama, Birmingham, AL. Electronic address: .
The Journal of pediatrics (Impact Factor: 3.74). 10/2012; 162(3). DOI: 10.1016/j.jpeds.2012.08.044
Source: PubMed

ABSTRACT OBJECTIVE: To report circuit characteristics and survival analysis in children weighing ≤10 kg enrolled in the Prospective Pediatric Continuous Renal Replacement Therapy (ppCRRT) Registry. STUDY DESIGN: We conducted prospective cohort analysis of the ppCRRT Registry to: (1) evaluate survival differences in children ≤10 kg compared with other children; (2) determine demographic and clinical differences between surviving and non-surviving children ≤10 kg; and (3) describe continuous renal replacement therapy (CRRT) circuit characteristics differences in children ≤5 kg versus 5-10 kg. RESULTS: The ppCRRT enrolled 84 children ≤10 kg between January 2001 and August 2005 from 13 US tertiary centers. Children ≤10 kg had lower survival rates than children >10 kg (36/84 [43%] versus 166/260 [64%]; P < .001). In children ≤10 kg, survivors were more likely to have fewer days in intensive care unit prior to CRRT, lower Pediatric Risk of Mortality 2 scores at intensive care unit admission and lower mean airway pressure (P(aw)), higher urine output, and lower percent fluid overload (FO) at CRRT initiation. Adjusted regression analysis revealed that Pediatric Risk of Mortality 2 scores, FO, and decreased urine output were associated with mortality. Compared with circuits from children 5-10 kg at CRRT initiation, circuits from children ≤5 kg more commonly used blood priming for initiation, heparin anticoagulation, and higher blood flows/effluent flows for body weight. CONCLUSION: Mortality is more common in children who are ≤10 kg at the time of CRRT initiation. Like other CRRT populations, urine output and FO at CRRT initiation are independently associated with mortality. CRRT prescription differs in small children.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: The incidence of acute kidney injury (AKI) has steadily increased in the last decade in neonates and infants. Despite the extensive proposed pharmacologic approaches to treat or prevent AKI, renal replacement therapy is the only available therapeutic approach to manage the consequences of significant AKI and maintain electrolyte homeostasis and fluid balance in infants with AKI. The objective of this article is to summarize the different approaches and modalities of renal replacement therapy in neonatal intensive care units.
    Clinics in Perinatology 09/2014; 41(3):517-527. DOI:10.1016/j.clp.2014.05.003 · 2.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The provision of continuous renal replacement therapies (CRRT) to small children has generally required the adaptation of adult machines and modified operational characteristics. CRRT prescription for younger and smaller children versus adults differs significantly due to problems concerning the extracorporeal blood volume, the need for circuit blood priming, and the adaptation of machines designed for adult-sized patients. Moreover, the provision of renal replacement therapy to infants and neonates presents a unique problem: no more than 10-15% of their blood volume should be removed by the extracorporeal circuit to prevent hypotension and anemia. In 2012, a dedicated machine, i.e. the Cardio-Renal, Pediatric Dialysis Emergency Machine (CARPEDIEM), was developed and launched the 'fitted era' for pediatric CRRT. In this review, we analyze how CRRT techniques have evolved for pediatric application and describe the first in vivo application of the CARPEDIEM for the safe and efficacious provision of CRRT to infants. © 2014 S. Karger AG, Basel.
    Nephron Clinical Practice 01/2014; 127(1-4):172-5. DOI:10.1159/000363204 · 1.65 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The effect of AKI and modern continuous RRT (CRRT) methods on drug disposition (pharmacokinetics) and response has been poorly studied. Pharmaceutical manufacturers have little incentive to perform pharmacokinetic studies in patients undergoing CRRT because such studies are neither recommended in existing US Food and Drug Administration (FDA) guidance documents nor required for new drug approval. Action is urgently needed to address the knowledge deficit. The Kidney Health Initiative has assembled a work group composed of clinicians and scientists representing academia, the FDA, and the pharmaceutical and dialysis industries with expertise related to pharmacokinetics, AKI, and/or CRRT. The work group critically evaluated key considerations in the assessment of pharmacokinetics and drug dosing in CRRT, practical constraints related to conducting pharmacokinetic studies in critically ill patients, and the generalizability of observations made in the context of specific CRRT prescriptions and specific patient populations in order to identify efficient study designs capable of addressing the knowledge deficit without impeding drug development. Considerations for the standardized assessment of pharmacokinetics and development of corresponding drug dosing recommendations in critically ill patients with AKI receiving CRRT are proposed.
    Clinical Journal of the American Society of Nephrology 09/2014; 10(1). DOI:10.2215/CJN.05630614 · 5.25 Impact Factor